Shire Limited , the global specialty biopharmaceutical company, notes that Jerini AG has announced today that the European Commission has granted the company marketing authorization for its lead compound FIRAZYR(R) (Icatibant) in the treatment of acute attacks of hereditary angioedema (HAE). HAE is a debilitating and potentially life-threatening genetic disease characterized by spontaneous and recurring attacks of edema.
The details can be read here.
No comments:
Post a Comment